Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

FDA Grants Priority Review to Sanofi's Venglustat for Type 3 Gaucher Disease

Sanofi's venglustat, an investigational oral glucosylceramide synthase inhibitor, has been granted priority review by the US FDA for the treatment of type 3 Gaucher disease (GD3). This marks a significant step towards providing the first US treatment specifically addressing the progressive neurological manifestations associated with GD3. The FDA's target action date for a decision is November 25, 2026. The New Drug Application is supported by positive data from the LEAP2MONO Phase 3 study, which demonstrated venglustat met both primary and three out of four key secondary endpoints, while also being well tolerated with no new safety signals.

• Regulatory Milestones for Venglustat: The FDA has granted venglustat priority review for type 3 Gaucher disease, underscoring its potential to address a critical unmet medical need. This follows previous designations including breakthrough therapy, fast-track, and orphan drug status in the US, EU, and Japan, highlighting the drug's significance for this rare lysosomal storage disorder.
• Positive Phase 3 Clinical Outcomes: The NDA is backed by robust data from the LEAP2MONO Phase 3 study, which evaluated venglustat in adults and pediatric patients with neurological manifestations of GD3. The study successfully met both its primary endpoints, focusing on neurological improvements, and three out of four key secondary endpoints, indicating broad efficacy and a favorable safety profile.
• Novel Mechanism for Neurological GD3: Venglustat is a brain-penetrant glucosylceramide synthase inhibitor designed to cross the blood-brain barrier. This unique mechanism allows it to target and inhibit the abnormal accumulation of glycosphingolipids in the central nervous system, which drives neuroinflammation and neurological symptoms in GD3, offering a potential first-in-class treatment for these specific manifestations.

Addressing the Unmet Neurological Needs in Type 3 Gaucher Disease

Type 3 Gaucher disease presents significant therapeutic challenges, particularly regarding neurological manifestations that remain largely unresponsive to current treatments. Despite advances in managing systemic symptoms, substantial limitations persist in addressing the complex neuronopathic features of this rare disorder.

• Limited neurological efficacy of standard therapies — Enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) fail to improve neurological function in Type 3 patients, despite demonstrating effectiveness for other disease manifestations

• Inadequate response to combination approaches — Patients with chronic neuronopathic disease show no significant improvements in hematological parameters or organ volumes when ERT is augmented with miglustat, indicating limited synergistic benefits

• Absence of disease-specific approved therapies — No treatments are specifically approved for Type 3 Gaucher disease, with current management limited to off-label use of ERT for symptom control with restricted efficacy

• High-risk intervention requirements — Stem cell transplantation offers potential neurological benefits but carries substantial procedural risks, limiting its applicability in clinical practice

• Accessibility and availability constraints — Patient needs remain unmet due to limited treatment availability, inaccessible disease sites, and the emergence of new disease manifestations not addressed by existing therapies

• Fundamental knowledge gaps — Deficiencies in understanding basic pathophysiological mechanisms continue to hinder the development of novel therapeutic approaches for this complex neuronopathic condition

Venglustat's Efficacy and Safety Profile from the LEAP2MONO Study

Recent research in Type 3 Gaucher disease has encompassed several distinct therapeutic approaches, from traditional enzyme replacement therapy to novel anti-inflammatory strategies and pharmacological chaperone development. A 2025 case report examined a GD3 patient with severe pulmonary involvement who was treated with systemic corticosteroids followed by hydroxychloroquine after initial enzyme replacement therapy proved insufficient for addressing respiratory manifestations. This patient, identified through neonatal screening and carrying compound heterozygous GBA1 variants, demonstrated clinical improvement with decreased inflammatory biomarkers (TNF-alpha and Pp38 MAPK levels), highlighting the potential role of anti-inflammatory and immunomodulatory therapies when ERT limitations become apparent.

The VPRIV study (NCT04721366), a phase IV observational study published in 2025, investigated velaglucerase alfa in 11 children with Gaucher disease (types 1 and 3) who initiated treatment before age 4 years. Patients received 60-80 U/kg doses administered weekly or every other week, predominantly in home settings, for durations ranging from 2-57 months. The study demonstrated excellent safety outcomes with no drug-related adverse events recorded, while efficacy measures showed improved or stable hematological values, organ sizes, and growth parameters across all patients, with glucosylsphingosine levels decreasing dramatically from 90-874 ng/mL to 4-26 ng/mL within six months of treatment initiation.

A 2026 stability study focused on developing high-dose ambroxol hydrochloride capsules for an n-of-1 clinical trial in Dutch Type 3 Gaucher patients, representing advancement in pharmacological chaperone therapy preparation. The 75 mg ambroxol hydrochloride formulation demonstrated robust stability profiles over six months under both accelerated and long-term storage conditions, with no degradation products above 0.05%, rapid dissolution kinetics (≥80% release within 30 minutes), and maintained content uniformity. This pharmaceutical development work supports the growing evidence base for high-dose ambroxol as a therapeutic option in neuronopathic Gaucher disease, providing the foundation for controlled clinical evaluation of this substrate reduction approach.

Venglustat's Place in the Evolving Type 3 Gaucher Treatment Landscape

The comparative data between investigational therapies and standard-of-care treatments for Type 3 Gaucher disease remains notably limited in the published literature. No randomized controlled trials have been identified that specifically compare investigational therapies to standard-of-care treatments for this chronic neuronopathic form of Gaucher disease. The limited evidence available comes primarily from observational studies and registry data, with Type 3 Gaucher disease representing only 5% of patients in the Gaucher Registry compared to 94% with Type 1 disease.

The most substantive comparative data involves substrate reduction therapy with miglustat as an adjunct to enzyme replacement therapy in patients with Type 3 Gaucher disease. In studies examining this combination approach, patients with neuronopathic Gaucher disease showed no significant improvements in hematological parameters such as hemoglobin concentration or platelet count, nor in organ volumes when enzyme replacement therapy was augmented with miglustat. These findings suggest that current standard-of-care approaches, including both enzyme replacement therapy and substrate reduction therapy, do not meaningfully improve neurological function in Type 3 patients.

Hematopoietic stem cell transplantation has been identified as a potential therapeutic option with possible long-term benefits for skeletal and neurological manifestations, including potential arrest or regression of neurological symptoms in neuronopathic forms. However, this high-risk procedure lacks robust clinical trial evidence, with systematic reviews through January 2017 identifying thirty-two trials but finding none suitable for evaluating comparative safety and efficacy against conservative measures like enzyme replacement therapy or substrate reduction therapy. The development of new small molecule therapies that may penetrate tissues inaccessible to enzyme replacement therapy represents a promising avenue, though progress remains hindered by incomplete understanding of basic pathophysiological mechanisms in Type 3 Gaucher disease.

Venglustat: A New Horizon for Neuropathic Gaucher Disease

The FDA's priority review for Sanofi's venglustat in type 3 Gaucher disease (GD3) signals a potential breakthrough for a patient population with profoundly limited treatment options. GD3 is a severe, progressive lysosomal storage disorder characterized by debilitating neurological symptoms that current enzyme replacement therapies (ERT) and existing substrate reduction therapies (SRT) largely fail to address. The literature consistently highlights the urgent need for small molecules capable of crossing the blood-brain barrier to impact these neuronopathic manifestations.

Venglustat, as an oral glucosylceramide synthase inhibitor, represents a targeted approach to reduce the accumulation of harmful glycosphingolipids. Its potential approval would not only establish a new standard of care for GD3 neurological symptoms but also validate the broader strategy of developing CNS-penetrating small molecule SRTs for other neurodegenerative lysosomal storage disorders. This could significantly reshape the competitive landscape, offering an oral alternative to intravenous ERTs and potentially outperforming other SRTs that have shown less consistent neurological benefits.

However, the path forward is not without considerations. While the Phase 3 data are positive, a qualitative study of venglustat in GD3 patients revealed instances where perceived benefits occurred despite low or undetectable drug levels in the cerebrospinal fluid, prompting questions about the consistency of CNS penetration and the direct mechanism of observed improvements. Furthermore, as with all therapies for rare diseases, the long-term safety profile and the economic implications of a potentially high-cost, continuously administered treatment will be critical factors influencing patient access and real-world adoption. The November 2026 target action date provides a substantial period for regulatory review, underscoring the complexity and significance of this potential new therapy.